769 related articles for article (PubMed ID: 36047968)
1. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
2. [Development of CAR-T Cells Effective against Solid Tumors].
Adachi K; Tamada K
Gan To Kagaku Ryoho; 2023 May; 50(5):577-583. PubMed ID: 37218315
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
4. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
Ohta K; Sakoda Y; Tamada K
Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
6. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
8. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
Qin Y; Xu G
Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
12. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
13. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
14. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.
Cherkassky L; Hou Z; Amador-Molina A; Adusumilli PS
Cancer Cell; 2022 Jun; 40(6):569-574. PubMed ID: 35487216
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
16. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
18. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H; Pan W
Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
[TBL] [Abstract][Full Text] [Related]
19. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
20. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
Schoenfeld AJ; O'Cearbhaill RE
Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]